-
公开(公告)号：WO2018136440A1
公开(公告)日：2018-07-26
申请号：PCT/US2018/013918
申请日：2018-01-16
Applicant: AMGEN INC.
Inventor： CHENG, Yuan , NETIROJJANAKUL, Chawita , HOLDER, Jerry Ryan , WU, Bin , FALSEY, James R. , HERBERICH, Bradley J. , SHAM, Kelvin , MIRANDA, Leslie P. , LU, Shu-Chen , VENIANT-ELLISON, Murielle M. , STANISLAUS, Shanaka , YIE, Junming , XU, Jing
IPC: A61K39/395 , C07K16/28 , A61P3/10
Abstract: Methods of treating metabolic diseases and disorders using a composition comprising an antigen binding protein specific for the GIPR polypeptide conjugated to a GLP-1 receptor agonist are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy. In certain embodiments the composition comprises an antibody or functional fragment thereof comprising a cysteine at one or more conjugation site(s) wherein the GLP-1 receptor agonist is conjugated to the antibody or functional fragment thereof through the side-chain of the cysteine residue.
-
公开(公告)号：WO2010129503A1
公开(公告)日：2010-11-11
申请号：PCT/US2010/033478
申请日：2010-05-04
Applicant: AMGEN INC. , BELOUSKI, Edward John , ELLISON, Murielle Marie , HAMBURGER, Agnes Eva , HECHT, Randy Ira , LI, Yue-Sheng , MICHAELS, Mark Leo , SUN, Jeonghoon , XU, Jing
Inventor： BELOUSKI, Edward John , ELLISON, Murielle Marie , HAMBURGER, Agnes Eva , HECHT, Randy Ira , LI, Yue-Sheng , MICHAELS, Mark Leo , SUN, Jeonghoon , XU, Jing
Abstract: The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions.
Abstract translation: 本发明提供编码FGF21突变多肽的核酸分子，FGF21突变多肽，包含FGF21突变多肽的药物组合物，以及使用此类核酸，多肽或药物组合物治疗代谢紊乱的方法。 >
-
公开(公告)号：WO2010042747A2
公开(公告)日：2010-04-15
申请号：PCT/US2009/060045
申请日：2009-10-08
Applicant: AMGEN INC. , WALKER, Kenneth W. , GEGG, Colin, V., Jr. , HECHT, Randy I. , BELOUSKI, Edward J. , LI, Yue-Sheng , MICHAELS, Mark L. , XU, Jing , ELLISON, Murielle M.
Inventor： WALKER, Kenneth W. , GEGG, Colin, V., Jr. , HECHT, Randy I. , BELOUSKI, Edward J. , LI, Yue-Sheng , MICHAELS, Mark L. , XU, Jing , ELLISON, Murielle M.
Abstract: The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions.
-
Patent Agency Ranking
公开(公告)号：WO2013033452A3
公开(公告)日：2013-03-07
申请号：PCT/US2012/053216
申请日：2012-08-30
Applicant: STANISLAUS, Shanaka , XU, Jing , AMGEN INC. , ELLISON, Murielle Marie
Inventor： STANISLAUS, Shanaka , XU, Jing , ELLISON, Murielle Marie
Abstract: Methods of treating metabolic diseases and disorders using a FGF21 polypeptide are provided. In various embodiments the metabolic disease or disorder is type 1 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels, diabetic nephropathy, neuropathy, retinopathy, ischemic heart disease, peripheral vascular disease and cerebrovascular disease
-
公开(公告)号：WO2017059371A1
公开(公告)日：2017-04-06
申请号：PCT/US2016/055017
申请日：2016-09-30
Applicant: AMGEN INC.
Inventor： XU, Jing , STANISLAUS, Shanaka , CHEN, Mei-Hsiu M. , HALE, Clarence H. , VENIANT-ELLISON, Murielle
CPC classification number: A61K38/1825
Abstract: The invention relates method of treating a patient in need thereof with a long acting agonist to the FGF21 signaling pathway. In a particular embodiment, the invention relates to the use of molecules that stimulate the FGF21 signaling pathway, such as long acting FGF21 polypeptides or agonist antibodies, to treat disorders or diseases associated with excess bile acid. The invention further relates to pharmaceutical formulations and dosing of long acting agonists of the FGF21 signaling pathway suitable for treating bile acid related disorders.
Abstract translation: 本发明涉及将有需要的患者用长效激动剂治疗FGF21信号通路的方法。 在一个具体实施方案中，本发明涉及刺激FGF21信号传导途径的分子（例如长效FGF21多肽或激动剂抗体）用于治疗与过量胆汁酸相关的疾病或疾病的用途。 本发明还涉及适用于治疗胆汁酸相关疾病的FGF21信号传导途径的长效激动剂的药物制剂和给药。
-
6.发明申请ANTIBODIES DIRECTED TO ANGIOPOIETIN-1 AND ANGIOPOIETIN-2 FOR OCULAR THERAPIES 审中-公开抗精神病药物1和抗胰岛素2的抗体用于眼科治疗
公开(公告)号：WO2016061551A1
公开(公告)日：2016-04-21
申请号：PCT/US2015/056091
申请日：2015-10-16
Applicant: AMGEN INC.
Inventor： LU, Shu-Chen , VENIANT-ELLISON, Murielle , XU, Jing , SALIMI-MOOSAVI, Hossein , OLINER, Jonathan D.
IPC: C07K16/22 , A61K39/395 , A61K39/00
CPC classification number: C07K16/22 , A61K2039/505 , A61K2039/54 , A61K2039/545 , C07K2317/31 , C07K2317/55 , C07K2317/76
Abstract: The present disclosure provides methods of treating ocular disorders using anti-angiogenic antibodies and pharmaceutical formulations.
Abstract translation: 本公开提供了使用抗血管生成抗体和药物制剂治疗眼部疾病的方法。
-
公开(公告)号：WO2010129600A2
公开(公告)日：2010-11-11
申请号：PCT/US2010/033614
申请日：2010-05-04
Applicant: AMGEN INC. , BELOUSKI, Edward John , ELLISON, Murielle Marie , HAMBURGER, Agnes Eva , HECHT, Randy Ira , LI, Yue-Sheng , MICHAELS, Mark Leo , SUN, Jeonghoon , XU, Jing
Inventor： BELOUSKI, Edward John , ELLISON, Murielle Marie , HAMBURGER, Agnes Eva , HECHT, Randy Ira , LI, Yue-Sheng , MICHAELS, Mark Leo , SUN, Jeonghoon , XU, Jing
IPC: A61K38/18
CPC classification number: C07K14/50 , A61K38/00 , C07K2319/30
Abstract: The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions.
-
公开(公告)号：WO2009149171A2
公开(公告)日：2009-12-10
申请号：PCT/US2009/046113
申请日：2009-06-03
Applicant: AMGEN INC. , BELOUSKI, Edward, John , ELLISON, Murielle, Marie , HAMBURGER, Agnes, Eva , HECHT, Randy, Ira , LI, Yue-Sheng , MICHAELS, Mark, Leo , SUN, Jeonghoon , XU, Jing
Inventor： BELOUSKI, Edward, John , ELLISON, Murielle, Marie , HAMBURGER, Agnes, Eva , HECHT, Randy, Ira , LI, Yue-Sheng , MICHAELS, Mark, Leo , SUN, Jeonghoon , XU, Jing
CPC classification number: C07K14/50 , A61K38/00 , A61K38/1825 , A61K2039/505 , C07K16/18 , C07K2319/30
Abstract: The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions.
Abstract translation: 本发明提供编码FGF21突变体多肽，FGF21突变体多肽，包含FGF21突变体多肽的药物组合物的核酸分子，以及使用此类核酸，多肽或药物组合物治疗代谢紊乱的方法。
-
-
-
-
-
-
-
Search Results
8
records
(took 0.021 seconds)
